1 Recommendations
Closed for comments This consultation ended on at Request commenting lead permission
2 Information about upadacitinib
Marketing authorisation indication
2.1 Upadacitinib (Rinvoq, AbbVie) is indicated 'for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to 1 or more disease-modifying antirheumatic drugs (DMARDs).' Upadacitinib may be used as monotherapy or in combination with methotrexate.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics.
Price
2.3 The list price for upadacitinib is £805.56 per 28‑day pack (company submission). The average cost for each patient per year is estimated at £10,508, based on the list price. The company has a commercial arrangement. This makes upadacitinib available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation